Guerbet : CA T1 2020 en ligne – Difficile de présager de l’après juin…- OC ajusté à 30.6 € (vs 34 €)
>T1 conforme, mais avec un mix un peu plus contrasté que prévu - Le CA T1 se monte à 199.2 M€, soit +1% ou +1.4% à tcc.. Le CA Rayons X progresse conformément aux dernières indications du management (107 M€ / +4.3%), le CA IRM consolide (64.4 M€ / -3%) et le CA RIT croit sensiblement (19.2 M€ / +15%), poursuivant ses gains de PdM (effet de ramp-up). Le différentiel de croissance entre Europe et RoW est plus marqué que nous l’attendions. En Europe, le CA baisse de 14.3...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.